Фузеон
Фузеон Uses, Dosage, Side Effects, Food Interaction and all others data.
Фузеон is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Trade Name | Фузеон |
Availability | Prescription only |
Generic | Enfuvirtide |
Enfuvirtide Other Names | Enfuvirtida, Enfuvirtide |
Related Drugs | Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild |
Type | |
Formula | C204H301N51O64 |
Weight | 4491.876 Da |
Protein binding | 92% |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Russia |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Фузеон is an HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
Фузеон is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
Фузеон is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
How Фузеон works
Фузеон binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. By disrupting the HIV-1 molecular machinery during its final stage of fusion with the target cell, enfuvirtide limits the spread of further infection. Фузеон is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion.
Food Interaction
No interactions found.Volume of Distribution
- 5.5 ± 1.1 L
Elimination Route
After a 90 mg single subcutaneous injection of Фузеон into the abdomen in 12 HIV-1 infected subjects, the mean peak concentration is 4.59+/-1.5 ug/ml and the median time to peak concentration was 8 hours (ranged from 3 to12 hours).
Half Life
3.8 +/- 0.6 hrs
Clearance
- 24.8 +/- 4.1 mL/h/kg [HIV-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide]
- 30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of FUZEON SC in combination with other antiretroviral agents in HIV-1 infected subjects]
- 40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose]
Innovators Monograph
You find simplified version here Фузеон